| 2024-11-18 | +1.04 % |
|
| 2024-11-14 | -2.31 % |
|
| 2024-11-06 | +0.7 % |
|
| 2024-11-04 | -0.62 % |
|
| 2024-11-01 | +0.3 % |
|
| 2024-10-31 | -0.71 % |
|
| 2024-10-30 | -0.02 % |
|
| 2024-10-24 | +0.55 % |
|
| 2024-10-23 | -0.22 % |
|
| 2024-10-22 | +6.85 % |
|
| 2024-10-18 | +0.46 % |
|
| 2024-10-16 | -0.28 % |
|
| 2024-10-15 | +0.23 % |
|
| 2024-10-14 | +0.22 % |
|
| 2024-10-07 | -2.58 % |
|
| 2024-09-26 | +1.27 % |
|
| 2024-09-25 | -0.39 % |
|
| 2024-09-09 | +0.89 % |
|
| 2024-08-06 | +0.75 % |
|
| 2024-07-24 | +2.09 % |
|
| 2024-07-23 | -4.34 % |
|
| 2024-07-19 | -0.57 % |
- The article describes a global IT outage caused by a content update from cyber security firm CrowdStrike affecting Windows computers worldwide, resulting in disruptions to banking, flights, payment systems, and supermarket operations, which may have caused Quest Diagnostics (DGX) stock to go down by -0.57% last night.
- Summary: A global IT outage described as the worst in history caused disruptions to various systems and services worldwide, with New Zealand companies affected by payment and network problems, leading to issues like supermarket checkouts going down and flight delays.
Reason for Quest Diagnostics (DGX) stock decline: The article does not mention any specific information about Quest Diagnostics being affected by the global IT outage, so it is unlikely that the stock decline in Quest Diagnostics was directly related to this event. The stock market performance is influenced by various factors such as company earnings, economic conditions, industry trends, and investor sentiment, rather than temporary IT outages.
|
| 2024-07-18 | -1.1 % |
|
| 2024-07-15 | +0.33 % |
- Truist Securities raised its price target for Quest Diagnostics (DGX) and maintained a Hold rating, citing strong base business trends, successful execution of growth opportunities, favorable operations including cost-saving initiatives and recent mergers and acquisitions, leading to a positive market outlook for the diagnostics industry and potential stock growth, ultimately resulting in an upward movement in Quest Diagnostics' stock price.
- Quest Diagnostics (DGX) stock went up by 0.33% last night, and the increase can be attributed to Fiduciary Management Inc.'s positive assessment of the company's market position as one of the largest independent clinical laboratory testing companies in the U.S., with a 24% market share, providing cost advantage, steady volume growth, and potential for mid-single-digit topline growth and high-single-digit earnings growth.
|
| 2024-07-05 | -0.32 % |
|
| 2024-06-13 | -0.22 % |
|
| 2024-06-07 | -0.21 % |
|
| 2024-06-04 | +0.33 % |
|
| 2024-06-03 | -0.61 % |
|
| 2024-05-30 | +0.82 % |
|
| 2024-05-23 | -1.28 % |
|
